Clinical Trials

91 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06008405 2023-09-06

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05005299 2023-08-01

VICTORY

LymphoidMyeloidOther hematologic neoplasmPlasma cell

18 enrolled

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05970822 2023-08-01

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

32 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05074550 2023-07-24

Safety Evaluation Study for Patients With Polycythemia Vera

6 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT05140811 2023-05-24

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

126 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05821738 2023-05-09

Avapritinib in CBF-AML With KIT Mutations

50 enrolled

Core Binding Factor Acute Myeloid Leukemia

NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Phase 3 Unknown

140 enrolled

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT05823714 2023-04-21

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

70 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05448599 2023-03-15

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05714592 2023-02-22

MYELOCARTOCH

300 enrolled

Myeloproliferative Disorders

NCT04226768 2022-10-04

Enhanced Palliative Care in MDS and AML

90 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04155411 2022-07-27

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Phase 4 Unknown

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05426798 2022-06-22

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

73 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04709458 2022-05-03

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

10 enrolled

Leukemia, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT04764513 2022-03-28

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

LymphoidMyeloidOther hematologic neoplasm

20 enrolled

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05001386 2022-03-17

ESAAC

LymphoidMyeloidOther hematologic neoplasmPlasma cell

800 enrolled

Hypersensitivity, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Hematologic Neoplasms

NCT05282719 2022-03-16

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

33 enrolled

Myelodysplastic-Myeloproliferative Diseases

NCT02602314 2022-01-20

SUSTRENIM

Phase 4 Unknown

450 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05175508 2022-01-03

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Phase 2/3 Unknown

180 enrolled

Frailty, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05115344 2021-11-10

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

31 enrolled

Myeloproliferative Disorders

NCT05084872 2021-10-20

HCQMa

Phase 2/3 Unknown

30 enrolled

Mastocytosis

NCT05080829 2021-10-18

Myeloid Mutations Register in R/R CML

29 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05066958 2021-10-04

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

LymphoidMyeloidOther hematologic neoplasm

20 enrolled

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Virus Diseases, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05061147 2021-10-01

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

100 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

37 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04999878 2021-08-11

RUE-DDGP

Phase 4 Unknown

30 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04370457 2021-08-04

MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

300 enrolled

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04429191 2021-06-11

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Classical hematologyMyeloidOther hematologic neoplasm

40 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04906031 2021-06-09

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

5 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01894477 2021-06-03

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

102 enrolled 12 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Neoplasm, Residual, Myelodysplastic-Myeloproliferative Diseases

NCT02530619 2021-05-26

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

26 enrolled 10 charts

Phase EARLY_PHASE1 Unknown

Leukemia, Megakaryoblastic, Acute, Primary Myelofibrosis

NCT03795779 2021-05-19

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

20 enrolled